Clinical trials for Lymphoma

101 currently recruiting clinical trials
Phase 2 Lymphoma #NCT06588478 #2024-515689-15-01
Required histologic types
B cell lymphoma
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
6 recruiting sites
Loxo Oncology
Phase 2 Lymphoma #NCT06588478 #2024-515689-15-01
Required histologic types
B cell lymphoma
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
6 recruiting sites
Loxo Oncology
Phase 2 Lymphoma CLL & Richter's syndrome #NCT04728893 #2023-504931-42-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Lymphoma #NCT04728893 #2023-504931-42-00
Required histologic types
B cell lymphoma
Required histologic sub types
Waldenström lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Targeted therapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Lymphoma #NCT04920617
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
ImmunoVaccine Technologies, Inc.
Phase 2 Lymphoma #NCT04128072
Required histologic types
T cell lymphoma
Required histologic sub types
Cutaneous T-cell lymphoma
Required disease stage
Early (stage I and II)
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 1 / Phase 2 Lymphoma #NCT07018752 #2024-514954-63-00
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
20 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 1 / Phase 2 Lymphoma #NCT07607925
Required histologic types
B cell lymphoma
Required disease stage
Disseminated (stage III and IV)
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Lymphoma #NCT07519772 #2025-523005-15-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Lymphoma #NCT07519772 #2025-523005-15-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Car-T Autologous stem cell transplant Allogeneic stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC